Swiss regulator gives green light to first drug to prevent Covid-19

16 September 2022 - Swissmedic has issued a temporary marketing authorisation for AstraZeneca’s drug Evusheld, making it the first Covid-19 prophylaxis ...

Read more →

Swissmedic authorizes Novavax Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 and as a booster in adults aged 18 and older

5 September 2022 - Novavax, today announced that Swissmedic has expanded its temporary authorisation of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in Switzerland ...

Read more →

Swissmedic authorises Novavax Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 and as a booster in adults aged 18 and older

2 September 2022 - Novavax today announced that Swissmedic has expanded its temporary authorisation of Nuvaxovid COVID-19 vaccine in Switzerland for ...

Read more →

Swissmedic authorises Moderna's Omicron targeting bivalent booster candidate MRNA-1273.214

29 August 2022 - Switzerland becomes among the first countries in the world to approve the use of a next-generation ...

Read more →

Kapruvia approved in Switzerland with additional regulatory decisions expected in H2, 2022

19 August 2022 - Regulatory decisions in Australia and Singapore expected by the end of 2022. ...

Read more →

Novavax files in Switzerland for expanded conditional marketing authorisation of Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 and as a booster in individuals aged 18 and over

7 July 2022 - Novavax today announced the submission of a request to Swissmedic to expand the conditional marketing authorisation ...

Read more →

BioCryst announces approval of Orladeyo (berotralstat) by Swissmedic

7 June 2022 -  -- BioCryst Pharmaceuticals today announced that Swissmedic has granted marketing authorisation for oral, once-daily Orladeyo (berotralstat) ...

Read more →

Swiss drug prices still soar above European levels

31 May 2022 - Compared with nine other European countries, Switzerland remains a high-price island for medicines, according to an annual ...

Read more →

Hansa Biopharma announces temporary marketing authorisation in Switzerland for Idefirix (imlifidase) in kidney transplantation

13 May 2022 - Idefirix is now granted marketing authorisation within the EU, the U.K., Israel and Switzerland. ...

Read more →

Swissmedic has accepted the new oral edarvarone formulation for the treatment of ALS

25 April 2022 - Mitsubishi Tanabe Pharma announced that Swissmedic has accepted the filing for an investigational oral suspension formalation ...

Read more →

Swissmedic grants conditional marketing authorisation for Novavax COVID-19 vaccine

13 April 2022 - Nuvaxovid is the first protein-based COVID-19 vaccine authorised for use in Switzerland. ...

Read more →

Switzerland approves its first protein-based Covid vaccine

15 April 2022 - Swissmedic announced its approval on Wednesday making Nuvaxovid the first protein-based vaccine to be licensed in Switzerland.  ...

Read more →

MorphoSys and Incyte announce Swissmedic temporary approval of Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adults with r/r DLBCL

22 March 2022 - Minjuvi is a new therapeutic option for eligible DLBCL patients in Switzerland addressing an urgent unmet medical ...

Read more →

BeiGene announces approval for Brukinsa (zanubrutinib) by Swissmedic for treatment of adult patients with Waldenström’s macroglobulinaemia

17 February 2022 - With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global ...

Read more →

Novavax files for conditional marketing authorisation of COVID-19 Vaccine in Switzerland

14 February 2022 - Novavax today announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional marketing authorisation ...

Read more →